Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Healthy Extracts (HYEX) EBITDA (2016 - 2025)

Healthy Extracts filings provide 11 years of EBITDA readings, the most recent being -$269282.0 for Q4 2025.

  • On a quarterly basis, EBITDA fell 38.73% to -$269282.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$943850.0, a 416.61% decrease, with the full-year FY2025 number at -$943850.0, down 415.35% from a year prior.
  • EBITDA hit -$269282.0 in Q4 2025 for Healthy Extracts, up from -$460113.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $85392.0 in Q3 2024 to a low of -$1.3 million in Q2 2023.
  • Median EBITDA over the past 5 years was -$257751.0 (2021), compared with a mean of -$308558.0.
  • Biggest five-year swings in EBITDA: tumbled 787.56% in 2023 and later soared 132.74% in 2024.
  • Healthy Extracts' EBITDA stood at -$662057.0 in 2021, then skyrocketed by 70.2% to -$197326.0 in 2022, then tumbled by 63.18% to -$321989.0 in 2023, then surged by 39.72% to -$194110.0 in 2024, then plummeted by 38.73% to -$269282.0 in 2025.
  • The last three reported values for EBITDA were -$269282.0 (Q4 2025), -$460113.0 (Q3 2025), and -$105607.0 (Q2 2025) per Business Quant data.